Cargando…

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

BACKGROUND: High frequencies of the BRAF V600E mutation have been reported in pleomorphic xanthoastrocytoma (PXA). Recently, a BRAF V600E mutation-specific antibody has been developed and validated. We evaluated the immunohistochemical (IHC) detection of BRAF V600E mutation in PXA by comparing to go...

Descripción completa

Detalles Bibliográficos
Autores principales: Ida, Cristiane M, Vrana, Julie A, Rodriguez, Fausto J, Jentoft, Mark E, Caron, Alissa A, Jenkins, Sarah M, Giannini, Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893490/
https://www.ncbi.nlm.nih.gov/pubmed/24252190
http://dx.doi.org/10.1186/2051-5960-1-20
_version_ 1782299699800178688
author Ida, Cristiane M
Vrana, Julie A
Rodriguez, Fausto J
Jentoft, Mark E
Caron, Alissa A
Jenkins, Sarah M
Giannini, Caterina
author_facet Ida, Cristiane M
Vrana, Julie A
Rodriguez, Fausto J
Jentoft, Mark E
Caron, Alissa A
Jenkins, Sarah M
Giannini, Caterina
author_sort Ida, Cristiane M
collection PubMed
description BACKGROUND: High frequencies of the BRAF V600E mutation have been reported in pleomorphic xanthoastrocytoma (PXA). Recently, a BRAF V600E mutation-specific antibody has been developed and validated. We evaluated the immunohistochemical (IHC) detection of BRAF V600E mutation in PXA by comparing to gold standard molecular analysis and investigating the interobserver variability of the IHC scoring. We performed BRAF V600E IHC in 46 cases, of which 37 (80%) cases had sufficient tumor tissue for molecular analysis. IHC detection was performed using monoclonal mouse antibody VE1 (Spring Bioscience). IHC slides were scored independently by four reviewers blind to molecular data, including a primary (gold standard) and three additional reviewers. BRAF V600E mutation status was assessed by allele-specific polymerase chain reaction (PCR) with fragment analysis. RESULTS: All 46 cases showed interpretable BRAF V600E IHC results: 27 (59%) were positive (strong cytoplasmic staining), 19 (41%) were negative (6 of these cases with focal/diffuse weak cytoplasmic staining, interpreted as nonspecific by the primary reviewer). By molecular analysis, all 37 cases that could be tested had evaluable results: 22 (59%) cases were positive for BRAF V600E mutation and were scored as “IHC-positive”, and 15 (41%) were negative (including 11 cases scored as “IHC-negative” and 4 cases scored as negative with minimal nonspecific staining). IHC detection of BRAF V600E mutant protein was congruent in all 37 cases that were successfully evaluated by molecular testing (sensitivity and specificity of 100%). Agreement for IHC scoring among the 4 reviewers was almost perfect (kappa 0.92) when cases were scored as “positive/negative” and substantial (kappa 0.78) when minimal nonspecific staining was taken into account. CONCLUSIONS: We conclude that detection of BRAF V600E mutation by immunohistochemistry is highly sensitive and specific. BRAF V600E IHC interpretation is usually straightforward, but awareness of possible nonspecific staining is necessary and training is recommended. It is a practical rapid method that may avoid the need of labor-intensive molecular testing and may be most valuable in small biopsies unsuitable for molecular analysis.
format Online
Article
Text
id pubmed-3893490
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38934902014-01-17 Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma Ida, Cristiane M Vrana, Julie A Rodriguez, Fausto J Jentoft, Mark E Caron, Alissa A Jenkins, Sarah M Giannini, Caterina Acta Neuropathol Commun Methodology Article BACKGROUND: High frequencies of the BRAF V600E mutation have been reported in pleomorphic xanthoastrocytoma (PXA). Recently, a BRAF V600E mutation-specific antibody has been developed and validated. We evaluated the immunohistochemical (IHC) detection of BRAF V600E mutation in PXA by comparing to gold standard molecular analysis and investigating the interobserver variability of the IHC scoring. We performed BRAF V600E IHC in 46 cases, of which 37 (80%) cases had sufficient tumor tissue for molecular analysis. IHC detection was performed using monoclonal mouse antibody VE1 (Spring Bioscience). IHC slides were scored independently by four reviewers blind to molecular data, including a primary (gold standard) and three additional reviewers. BRAF V600E mutation status was assessed by allele-specific polymerase chain reaction (PCR) with fragment analysis. RESULTS: All 46 cases showed interpretable BRAF V600E IHC results: 27 (59%) were positive (strong cytoplasmic staining), 19 (41%) were negative (6 of these cases with focal/diffuse weak cytoplasmic staining, interpreted as nonspecific by the primary reviewer). By molecular analysis, all 37 cases that could be tested had evaluable results: 22 (59%) cases were positive for BRAF V600E mutation and were scored as “IHC-positive”, and 15 (41%) were negative (including 11 cases scored as “IHC-negative” and 4 cases scored as negative with minimal nonspecific staining). IHC detection of BRAF V600E mutant protein was congruent in all 37 cases that were successfully evaluated by molecular testing (sensitivity and specificity of 100%). Agreement for IHC scoring among the 4 reviewers was almost perfect (kappa 0.92) when cases were scored as “positive/negative” and substantial (kappa 0.78) when minimal nonspecific staining was taken into account. CONCLUSIONS: We conclude that detection of BRAF V600E mutation by immunohistochemistry is highly sensitive and specific. BRAF V600E IHC interpretation is usually straightforward, but awareness of possible nonspecific staining is necessary and training is recommended. It is a practical rapid method that may avoid the need of labor-intensive molecular testing and may be most valuable in small biopsies unsuitable for molecular analysis. BioMed Central 2013-05-30 /pmc/articles/PMC3893490/ /pubmed/24252190 http://dx.doi.org/10.1186/2051-5960-1-20 Text en Copyright © 2013 Ida et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology Article
Ida, Cristiane M
Vrana, Julie A
Rodriguez, Fausto J
Jentoft, Mark E
Caron, Alissa A
Jenkins, Sarah M
Giannini, Caterina
Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
title Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
title_full Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
title_fullStr Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
title_full_unstemmed Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
title_short Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
title_sort immunohistochemistry is highly sensitive and specific for detection of braf v600e mutation in pleomorphic xanthoastrocytoma
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893490/
https://www.ncbi.nlm.nih.gov/pubmed/24252190
http://dx.doi.org/10.1186/2051-5960-1-20
work_keys_str_mv AT idacristianem immunohistochemistryishighlysensitiveandspecificfordetectionofbrafv600emutationinpleomorphicxanthoastrocytoma
AT vranajuliea immunohistochemistryishighlysensitiveandspecificfordetectionofbrafv600emutationinpleomorphicxanthoastrocytoma
AT rodriguezfaustoj immunohistochemistryishighlysensitiveandspecificfordetectionofbrafv600emutationinpleomorphicxanthoastrocytoma
AT jentoftmarke immunohistochemistryishighlysensitiveandspecificfordetectionofbrafv600emutationinpleomorphicxanthoastrocytoma
AT caronalissaa immunohistochemistryishighlysensitiveandspecificfordetectionofbrafv600emutationinpleomorphicxanthoastrocytoma
AT jenkinssarahm immunohistochemistryishighlysensitiveandspecificfordetectionofbrafv600emutationinpleomorphicxanthoastrocytoma
AT gianninicaterina immunohistochemistryishighlysensitiveandspecificfordetectionofbrafv600emutationinpleomorphicxanthoastrocytoma